Concepedia

Author

Thomas A. Pires

Seagen (United States)ORCID

Also Known As

Thomas A Pires, Thomas A. Pires, Thomas Pires

53

Publications

176

Citations

7

H-Index

43

Concepts

All Affiliations

Seagen (United States)University of Illinois Urbana-Champaign
TA

About

Thomas A. Pires is an author at Seagen (United States) specializing in medicine, immunotherapy, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

121

2

Natural Sciences

3

3

102

3

Biochemistry

3

3

98

4

Engineering

2

2

38

5

Biomolecular Engineering

2

2

88

Thomas A. Pires

×

7

Publications

170

Citations

7

H-Index

YearCitations

Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates

Patrick Burke, Joseph Z. Hamilton, Thomas A. Pires,

Molecular Cancer Therapeutics

2016

60

Substrate interactions guide cyclase engineering and lasso peptide diversification

Susanna E. Barrett, Yin Song, Peter Jordan,

Nature Chemical Biology

2024

28

Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models

Patrick Burke, Joseph Z. Hamilton, Thomas A. Pires,

Molecular Cancer Therapeutics

2018

21

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

Rebecca Mazahreh, Marsha L. Mason, John J. Gosink,

Molecular Cancer Therapeutics

2023

21

Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract

Ségolène Gendreau, Raphaël Porcher, Benjamin Thoreau,

Seminars in Arthritis and Rheumatism

2021

16

Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation

Joseph Z. Hamilton, Thomas A. Pires, Jamie Mitchell,

ChemMedChem

2020

14

Effects of Cationic Proteins on Gold Nanoparticle/Aptamer Assays

Thomas A. Pires, Conor M. Narovec, Rebecca J. Whelan

ACS Omega

2017

10

Page 1